TransEnterix, Inc., a medical device company, focuses on the development and commercialization of surgical robotic systems. The company offers ALF-X System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. The company also develops SurgiBot System, a single-incision, patient-side robotic-assisted surgery system. In addition, it develops and manufactures flexible and rigid laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Apparently TRXC is getting a good pump job from this wonderful place: Caution, audio autoplays! http://pro.moneymappress.com/ERNRBT/EERNS454/
TransEnterix shares soar on FDA clearance of robotic surgery device http://www.marketwatch.com/story/tr...ry-device-2017-10-13?siteid=yhoof2&yptr=yahoo
Been flipping this last couple of weeks. Very volatile. I am considering scaling in long once it settles down. If they can get just a small portion of the US robotic sales this could fly long term.
TransEnterix shares soar on FDA clearance of robotic surgery device. But it didn't have any significant and steady raising meaning in stock prices, unfortunately.
TransEnterix Announces Senhance US Sale Agreement With Florida Hospital - https://finance.yahoo.com/news/transenterix-announces-senhance-us-sale-134500554.html
Awesome! I've got several thousand shares in 401K account, plus I been trading as well in my trade account. If the sales start coming in the big guy on the bloc may consider it a threat and try to eliminate it.
Short group uses the liquidity for an opportunity. Makes this very tradable. https://finance.yahoo.com/news/short-report-claims-transenterixs-senhance-170414724.html
TransEnterix Announces Global SurgiBot System Agreement - https://finance.yahoo.com/news/transenterix-announces-global-surgibot-system-111000658.html
But SurgiBot has not been approved in any country. Hoping there would be no troubles and delays in retaining rights to co-promote SurgiBot outside of China.
A lot of catalysts have propelled this over the last month. TransEnterix, Inc. Reports Operating and Financial Results for the First Quarter 2018 4:05 pm ET May 8, 2018 (BusinessWire) Print TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the first quarter 2018. Recent Highlights -- During the first quarter ended March 31, 2018, the Company sold two Senhance Systems -- In January of 2018, the Company filed a FDA 510(k) submission to expand the indications for use of the Senhance System, potentially doubling the Senhance System's total addressable procedures -- Thus far in the second quarter ending June 30, 2018, the Company has sold three Senhance Systems, including one in the U.S. "We continued to generate momentum in the first quarter of 2018, including delivering the second consecutive quarter with multiple Senhance system sales and progressing our U.S. indication expansion strategy," said Todd M. Pope, President and CEO at TransEnterix. "Looking to the balance of 2018, we will continue to leverage the momentum we have generated to drive the global commercial adoption of Senhance." Commercial and Clinical Update In the quarter ended March 31, 2018, the Company sold two Senhance Systems. Both of these sales have come from sales to end user hospitals by distributors in the Company's EMEA (Europe, Middle East, and Africa) region. In January of 2018, the Company filed a 510(k) submission with the FDA to expand the indications for use of the Senhance System to include laparoscopic inguinal hernia and gallbladder surgery. The Senhance System is currently cleared for use in the U.S. for laparoscopic colorectal and laparoscopic gynecologic surgery, accounting for approximately 1.5 million procedures in the U.S. annually. Upon clearance, we anticipate these additional indications would bring the Senhance System's total addressable procedures in the U.S. to approximately 3 million. Thus far in the quarter ending June 30, 2018, the Company has sold three Senhance Systems. One of the system sales was in the U.S., driven by the Company's direct sales force, the remaining two system sales came from sales to end user hospitals by distributors in the Company's EMEA region. First Quarter Financial Highlights For the three months ended March 31, 2018, the Company reported revenue of $4.8 million as compared to revenue of $1.9 million in the three months ended March 31, 2017. Revenue in the first quarter of 2018 included $3.5 million in system sales, $1.1 million in instruments and accessories, and $200 thousand in services. For the three months ended March 31, 2018, total net operating income and expenses were $5.4 million, as compared to $16.5 million in the three months ended March 31, 2017. For the three months ended March 31, 2018, net loss was $0.9 million, or $0.00 per share, as compared to a net loss of $15.4 million, or $0.13 per share, in the three months ended March 31, 2017. For the three months ended March 31, 2018, adjusted net loss was $11.3 million, or $0.06 per share, as compared to an adjusted net loss of $12.6 million, or $0.11 per share in the three months ended March 31, 2017, after adjusting for the gain from the sale of SurgiBot assets and non-cash charges for amortization of intangible assets, change in fair value of contingent consideration, and change in fair value of warrant liabilities. Conference Call TransEnterix, Inc. will host a conference call on Tuesday, May 8, 2018 at 4:30 PM ET to discuss its first quarter 2018 operating and financial results. To listen to the conference call on your telephone, please dial (844) 804-5261 for domestic callers or (612) 979-9885 for international callers and reference conference ID 4854118 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm. The replay will be available on the Company's website. TransEnterix Wins FDA Approval For Expanded Indications For Senhance Surgical System -- MarketWatch 7:03 am ET May 29, 2018 (MarketWatch) Share Print TransEnterix Announces LSU Health Completes Purchase of Senhance Surgical System Business Wire•May 31, 2018 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- ™ Surgical System. The Senhance has been installed at University Medical Center New Orleans (UMC New Orleans).">TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that LSU Health completed the purchase of the Company’s Senhance™ Surgical System. The Senhance has been installed at University Medical Center New Orleans (UMC New Orleans). UMC New Orleans is home to the Reverend Avery C. Alexander Academic Research Hospital, and is an academic medical center in partnership with LSU Health New Orleans, Tulane University School of Medicine, and other local colleges and universities. UMC New Orleans will be a center for clinical excellence utilizing the Senhance Surgical System in general, colorectal and gynecologic surgery. The Senhance Surgical System represents an innovative technology designed to assist surgeons in performing minimally invasive surgery. While seated comfortably at a console, the surgeon uses multiple robotic arms to control small surgical instruments with robotic precision while at the same time moving a small scope that tracks the eye movement of the surgeon. The Senhance is the first surgical robotic system to offer the security of haptic force feedback that allows surgeons to feel the forces the instruments generate when handling delicate tissue. “We are pleased that LSU Health New Orleans is beginning its digital laparoscopy program using the Senhance Surgical system,” said Todd M. Pope, President and CEO at TransEnterix. “Our system is designed to support responsible economics for the hospital, and we look forward to partnering with the surgeons at UMC New Orleans to advance patient care in ways that matter in today's value-based healthcare landscape.” “LSU Health New Orleans and University Medical Center New Orleans see the Senhance Surgical System as an important and necessary advance in surgical care,” said Dr. Guy Orangio FACS, FASCRS, Chief Section of Colorectal Surgery at LSU Health New Orleans, and President of the American Society of Colon and Rectal Surgeons. “This new robotic system brings enabling technology with haptic feedback and innovative surgeon camera control while minimizing costs and maintaining existing efficiencies.” “Patients are seeking minimally invasive options that utilize the most advanced technology to treat gynecologic conditions,” said Dr. Lisa M. Peacock, Chairperson of the Department of Obstetrics and Gynecology, and Section Head and Program Director of Female Pelvic Medicine and Reconstructive Surgery at LSU Health New Orleans. ”As an academic medical center, we believe this new robotic surgical platform will play an important role in our continued leadership in surgical teaching, research, and providing excellent patient care.” On May 29, 2018, TransEnterix announced that it received FDA 510(k) clearance for laparoscopic inguinal hernia and laparoscopic cholecystectomy (gallbladder removal) procedures, doubling its total addressable market in the U.S. to over three million annual procedures. In the U.S., Senhance is now cleared for laparoscopic colorectal, gynecologic, inguinal hernia and cholecystectomy surgery. TransEnterix Announces FDA 510(k) Submission for 3mm Senhance Instruments 4:05 pm ET June 7, 2018 (BusinessWire) Print TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the Company filed a FDA 510(k) submission for additional Senhance System instruments including 3 millimeter diameter instruments. The clearance of these instruments would allow the Senhance to be used for microlaparoscopic surgeries, allowing surgeons to make tiny incisions that are deemed virtually scarless for patients. "TransEnterix is the first company to seek FDA clearance for robotically-driven 3 millimeter instruments for abdominal surgery in the U.S.," said Todd M. Pope, TransEnterix CEO. "We believe Senhance robotic assistance can enable surgeons to expand their use of virtually scarless surgery in more patients, and expands the value that robotics can bring over traditional manual approaches." "Microlaparoscopy is the current frontier in the process of reducing invasiveness, pain, scarring and opioid use post-surgery," said Dr. Steven D. McCarus, MD, FACOG, Chief of Gynecologic Surgery at Florida Hospital Celebration Health. "With Senhance, robotic microlaparoscopic surgery is a reality, bringing precision, control and sensitive force feedback to the use of these tiny surgical instruments. Surgeons have not had the ability to use such small instruments with a robotic surgical platform before, and this offers patients an attractive, virtually scarless approach to many surgeries." In the U.S., Senhance is cleared for laparoscopic colorectal, gynecologic, inguinal hernia and cholecystectomy surgery, enabling Senhance to be used in over 3 million procedures per year, including some of the most common abdominal surgeries in general surgery and gynecology.
